Tumor Immunology

Research aim

Our research aims to revolutionise cancer treatment by advancing innovative immunotherapies, ensuring safer, more effective therapies, and improving patient outcomes, ultimately transforming lives through cutting-edge translational cancer research.

About us

The Tumor Immunology Group advances cancer research and immunotherapy through a multidisciplinary approach, integrating immune receptor techniques, predictive modelling, soluble therapeutic formats, and advanced therapy medicinal products (ATMPs). By bridging academic discoveries with clinical applications, the group accelerates the development of innovative treatments.The group focuses on αβ and γδ T cells, whose receptors target tumours, including those with low mutation loads, while sparing normal tissues. These findings drive the development of precise immunotherapies. Predictive modelling uses advanced 3D models and AI-enhanced multiomics approaches to understand immune effector cells, guiding early-stage decisions on promising therapeutic candidates. In soluble therapeutic formats, bispecific T cell engagers are developed to enhance the precision and efficacy of protein-based cancer therapies using innate immune receptors. The group leads ATMP development, employing GMP simulation facilities to ensure the safety and quality of therapies transitioning to clinical trials. Clinical validation efforts focus on immune therapies for hematological malignancies, particularly in allogeneic stem cell transplantation. Cohort studies and trials ensure safe translation into clinical practice.